Phase III Study of Gemcitabine/Oxaliplatin (GEMOX) With or Without Erlotinib in Unresectable, Metastatic Biliary Tract Carcinoma
This is a phase III study of Gemcitabine/Oxaliplatin (GEMOX) with or without Erlotinib in
unresectable, metastatic biliary tract carcinoma.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression Free Survival
every 6 weeks
Yes
Ho yeong Lim, M.D,Ph.D
Principal Investigator
Samsung Medical Center, Seoul, Korea
Korea: Food and Drug Administration
2008-12-024
NCT01149122
January 2009
June 2012
Name | Location |
---|